Key Takeaways
- Shares of ImmunityBio (IBRX) increased 3% Monday following the company’s formal FDA compliance submission
- FDA officials identified a television commercial and podcast discussing Anktiva as potentially problematic in March 2026
- The company clarified that the television commercial cited by regulators never reached audiences; the podcast has been taken down from company channels
- Leadership training requirements and enhanced promotional review procedures are being established
- Preliminary results from QUILT-2.005 trial demonstrate sufficient statistical power for planned Q4 2026 supplemental regulatory submission
Shares of ImmunityBio (IBRX) advanced 3% Monday following the biotechnology company’s formal submission addressing FDA questions about promotional activities surrounding Anktiva, its bladder cancer treatment.
Regulators from the FDA’s Office of Prescription Drug Promotion issued correspondence dated March 13, 2026, raising concerns about a television commercial and a podcast episode, describing both as potentially misleading communications.
The company contested specific aspects of the agency’s assertions. According to ImmunityBio, the television commercial referenced by federal regulators never appeared on broadcast channels or reached any public audience.
The podcast featured statements from Founder and Executive Chairman Dr. Patrick Soon-Shiong. According to the company’s explanation, his remarks represented forward-looking perspectives on the development pipeline rather than assertions about currently authorized therapeutic uses.
ImmunityBio has withdrawn the podcast episode from its official website and contacted third-party distribution platforms to request removal from those channels as well.
CEO Richard Adcock emphasized that promotional compliance represents a critical priority for the organization. He underscored the importance of maintaining clear distinctions between investigational programs and authorized therapeutic applications.
The company’s corrective measures include instituting required compliance training for executives, strengthening Promotional Review Committee procedures, and engaging outside regulatory advisors to evaluate future high-profile communications.
Litigation Concerns Emerge
The regulatory correspondence has generated consequences beyond federal oversight. Several law firms have initiated securities class action litigation, claiming shareholders received misleading information about Anktiva’s therapeutic profile and the company’s marketing conduct.
This represents a significant concern for stakeholders. Regardless of how regulators ultimately view the company’s response, ongoing litigation creates additional uncertainty for investors monitoring a business facing substantial operating losses and revenue concentration in a single therapeutic product.
Clinical Development Continues Advancing
Amid regulatory scrutiny, Anktiva’s clinical program has maintained momentum. Preliminary findings from the pivotal QUILT-2.005 study revealed that an independent data monitoring committee validated the 366-patient randomized investigation — evaluating Anktiva combined with BCG versus BCG monotherapy — as appropriately designed for the anticipated supplemental BLA submission scheduled for Q4 2026.
This regulatory submission would address BCG-naïve non-muscle invasive bladder cancer patients, representing label expansion beyond Anktiva’s existing authorization.
Anktiva received approval for use alongside Bacillus Calmette-Guérin in adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer presenting with carcinoma in situ, either alone or with papillary tumors.
Financial analysts present divergent projections. Conservative models anticipate $1.2 billion in revenue generation and $435.5 million in earnings by 2029 — necessitating approximately 119% compound annual revenue growth from current operating losses of -$351.4 million.
Optimistic forecasts project revenue reaching $1.6 billion with earnings of $671.9 million by that timeframe.
The Q4 2026 supplemental BLA submission represents the nearest-term catalyst for the company.
